World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
28845
World Ranking
12229
National Ranking
31

Roberto Giugliani publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Roberto Giugliani sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 878 publications — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Roberto Giugliani D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Roberto Giugliani sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Roberto Giugliani is affiliated with the Federal University of Rio Grande do Sul in Brazil. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, evidenced by their significant publication record. The main areas of study include Physiology, Molecular Biology, Epidemiology, Genetics, and Rheumatology.

The scientist's work extensively covers topics such as Lysosomal Storage Disorders Research, Trypanosoma species research and implications, Glycogen Storage Diseases and Myoclonus, Autoimmune and Inflammatory Disorders Research, Biomedical Research and Pathophysiology, Carbohydrate Chemistry and Synthesis, and Sphingolipid Metabolism and Signaling.

Roberto Giugliani contributes frequently to several scientific journals and has a considerable number of publications in venues including:

  • Molecular Genetics and Metabolism
  • Orphanet Journal of Rare Diseases
  • American Journal of Medical Genetics Part A
  • Molecular Genetics and Metabolism Reports
  • Journal of Inborn Errors of Metabolism and Screening

Notable recent papers by Roberto Giugliani include:

  • "A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results," 2022, Genetics in Medicine
  • "One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency," 2021, Genetics in Medicine
  • "Diagnosis of Mucopolysaccharidoses," 2020, Diagnostics
  • "Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial," 2020, Molecular Genetics and Metabolism
  • "Consensus clinical management guidelines for acid sphingomyelinase deficiency (Niemann-Pick disease types A, B and A/B)," 2023, Orphanet Journal of Rare Diseases

Collaborations form an important part of their scientific activity. Frequent co-authors associated with Roberto Giugliani are:

  • Maurizio Scarpa
  • Francyne Kubaski
  • Guilherme Baldo
  • Ana Carolina Brusius-Facchin
  • Paul Harmatz

Roberto Giugliani's extensive work contributes to understanding rare metabolic and genetic disorders through a multidisciplinary approach involving clinical trials, pathology, and molecular studies. The research output reflects ongoing efforts to investigate enzyme replacement therapies and diagnostic methods for lysosomal storage disorders and related diseases.

Best Publications

  • Epidemiology of mucopolysaccharidoses

    Shaukat A. Khan;Hira Peracha;Diana Ballhausen;Alfred Wiesbauer

  • A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

    Joseph Muenzer;James E Wraith;Michael Beck;Roberto Giugliani

  • Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

    Dominique P Germain;Derralynn A Hughes;Kathleen Nicholls;Daniel G Bichet

  • Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)

    Rick Martin;Michael Beck;Christine Eng;Roberto Giugliani

  • Management guidelines for mucopolysaccharidosis VI.

    Roberto Giugliani;Paul Harmatz;James E. Wraith

  • Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey

    A Mehta;J T R Clarke;R Giugliani;P Elliott

  • Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

    A. Mehta;M. Beck;P. Elliott;R. Giugliani

  • Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.

    Paul Harmatz;Roberto Giugliani;Ida Schwartz;Nathalie Guffon

  • Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

    Elizabeth A. Braunlin;Paul R. Harmatz;Maurizio Scarpa;Beatriz Furlanetto

  • Genetics of homocysteine metabolism and associated disorders.

    S. Brustolin;R. Giugliani;T. M. Félix

  • Multidisciplinary Management of Hunter Syndrome

    Joseph Muenzer;M Beck;C M Eng;M L Escolar

  • Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment

    Giugliani R;Federhen A;Rojas Mv;Vieira T

  • The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families

    Maria Isabel Waddington Achatz;Magali Olivier;Florence Le Calvez;Ghyslaine Martel-Planche

  • Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

    Joseph Muenzer;Michael Beck;Christine M Eng;Roberto Giugliani

  • Primary renal hypoplasia in humans and mice with PAX2 mutations: evidence of increased apoptosis in fetal kidneys of Pax21Neu +/– mutant mice

    Sarah Porteous;Elena Torban;Nam-Pyo Cho;Heather Cunliffe

  • An international classification of inherited metabolic disorders (ICIMD).

    Carlos R Ferreira;Shamima Rahman;Shamima Rahman;Markus Keller;Johannes Zschocke

  • The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

    Elfrida R. Benjamin;Maria Cecilia Della Valle;Xiaoyang Wu;Evan Katz

  • Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study

    Christian J. Hendriksz;Christian J. Hendriksz;Barbara Burton;Thomas R. Fleming;Paul Harmatz

  • Initial report from the Hunter Outcome Survey.

    J. Edmond Wraith;Michael Beck;Roberto Giugliani;Joe Clarke;Joe Clarke

  • Inborn Errors of Metabolism Sensitivity of Screening Tests in High Risk Patients

    Roberto Giugliani;Carlos S. Dutra-Filho;Maria L. Barth;Janice C. Dutra

Frequent Co-Authors

Derralynn Hughes
Derralynn Hughes Royal Free London NHS Foundation Trust
Shunji Tomatsu
Shunji Tomatsu Alfred I. duPont Hospital for Children
Moacir Wajner
Moacir Wajner Federal University of Rio Grande do Sul
Daniel G. Bichet
Daniel G. Bichet University of Montreal
Yasuyuki Suzuki
Yasuyuki Suzuki Gifu University
Tadao Orii
Tadao Orii Gifu University
Seiji Yamaguchi
Seiji Yamaguchi Shimane University
Simon Jones
Simon Jones Microsoft (United States)
Raphael Schiffmann
Raphael Schiffmann Baylor University
Frits A. Wijburg
Frits A. Wijburg University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA is a rigorous journey, several alternative online degrees and career pathways can help you enter the healthcare field or complement your medical education. Many students choose online BSN programs for non nurses, which provide a flexible and efficient path to becoming a registered nurse without a prior nursing background.

If you prefer an administrative or non-clinical role, exploring one of the best online medical billing and coding schools can lead to solid career opportunities in healthcare documentation and billing. These programs are often offered entirely online, making them accessible for working adults or career changers.

Prospective nurses concerned about entrance exams should consider schools on the list of do you have to take a teas test for lpn. These schools may offer entry without the common TEAS or HESI test requirements.

For those interested in leadership roles, accredited healthcare administration degree programs can prepare you for management positions in medical facilities, often through accelerated online study formats.

Best Scientists Citing Roberto Giugliani

Trending Scientists

Recently Published Articles